The law firm of Slater Slater Schulman LLP is investigating complaints that type 2 diabetes treatment Victoza® may be associated with pancreatic cancer, as well as allegations that Victoza’s manufacturers negligently marketed and promoted the drug and failed to adequately test it or warn consumers of the risks of pancreatic cancer.

About Onglyza

On March 14, 2013, the FDA released a Drug Safety Communication concerning Victoza, Onglyza, Januvia, Byetta and others in the same class of drugs, stating:

The U.S. Food and Drug Administration (FDA) is evaluating unpublished new findings by a group of academic researchers that suggest an increased risk of pancreatitis, or inflammation of the pancreas, and pre-cancerous cellular changes called pancreatic duct metaplasia in patients with type 2 diabetes treated with a class of drugs called incretin mimetics.

Drugs in this class work by mimicking the incretin hormones produced by the body to stimulate the release of insulin after ingesting food. Together with exercising and eating better, these drugs can help lower blood sugar levels in adults with type 2 diabetes.

While there were previous studies suggesting Victoza and other incretin drugs, including Onglyza, Januvia, Byetta, may been linked to pancreatitis, this recent FDA statement raises the possibility that Victoza, Onglyza, Januvia, Byetta may also be associated with pancreatic cancer.

Do I have a Onglyza Cancer Lawsuit?

The attorneys at Slater Slater Schulman LLP are dedicated to assisting potential plaintiffs in Victoza pancreatic cancer lawsuits. If you or someone you love have taken Victoza,Onglyza, Januvia, Byetta and developed pancreatic cancer, you should contact Slater Slater Schulman LLP for a free consultation by filling out the form on this page or by calling us at (800) 251-6990.


Medical disclaimer: Please note that any change in medications should be made only after consulting with your doctor about the risks and benefits of doing so, and should not be based on any information contained in this web site or on a commercial.